Lysophosphatidylcholine regulates human microvascular endothelial cell expression of chemokines

Journal of Molecular and Cellular Cardiology

Volumn 35, Issue 11, 2003, Pages 1375-1384

  Murugesan, Gurunathan ^a   Rani, M R Sandhya ^a   Gerber, Christina E ^a   Mukhopadhyay, Chaitali ^a   Ransohoff, Richard M ^a   Chisolm, Guy M ^a   Kottke Marchant, Kandice ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Chemokines; Endothelial cells; IL 8; Lysophosphatidylcholine: MAP kinase; MCP 1; PI3 kinase; RANTES

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; CHEMOKINE; GINKGOLIDE B; INTERLEUKIN 8; LYSOPHOSPHATIDYLCHOLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PERTUSSIS TOXIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RANTES; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA;

AORTA; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PULMONARY ARTERY; SIGNAL TRANSDUCTION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

EID: 0242352325     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2003.08.004     Document Type: Article

References (52)

1. Krishnaswamy G., Kelley J., Yerra L., Smith J.K., Chi D.S. Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J Interf Cytokine Res. 19:1999;91-104.
2. Luster A.D. Chemokines - chemotactic cytokines that mediate inflammation. New Engl J M. 338:1998;436-445.
3. Ross R. Atherosclerosis - an inflammatory disease. New Engl J M. 340:1999;115-126.
4. Hurt-Camejo E., Camejo G., Peilot H., Oorni K., Kovanen P. Phospholipase A(2) in vascular disease. Circ Res. 89:2001;298-304.
5. Murugesan G., Fox P.L. Role of lysophosphatidylcholine in the inhibition of endothelial cell motility by oxidized low density lipoprotein. J Clin Invest. 97:1996;2736-2744.
6. Chisolm G.M., Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol M. 28:2000;1815-1826.
7. Kume N., Gimbrone M.A. Jr. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest. 93:1994;907-911.
8. Kita T., Kume N., Ochi H., Nishi E., Sakai A., Ishii K., et al. Induction of endothelial platelet-derived growth factor-B-chain and intercellular adhesion molecule-1 by lysophosphatidylcholine. Ann NY Acad Sci. 811:1997;70-75.
9. Cybulsky M.I., Gimbrone M.A. Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 251:1991;788-791.
10. Murohara T., Scalia R., Lefer A.M. Lysophosphatidylcholine promotes P-selectin expression in platelets and endothelial cells. Possible involvement of protein kinase C activation and its inhibition by nitric oxide donors. Circ Res. 78:1996;780-789.
11. Kume N., Cybulsky M.I., Gimbrone M.A. Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest. 90:1992;1138-1144.
12. Berliner J.A., Navab M., Fogelman A.M., Frank J.S., Demer L.L., Edwards P.A., et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 91:1995;2488-2496.
13. Takahara N., Kashiwagi A., Maegawa H., Shigeta Y. Lysophosphatidylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells. Metabolism. 45:1996;559-564.
14. Quinn M.T., Parthasarathy S., Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA. 85:1988;2805-2809.
15. Murphy A.A., Santanam N., Morales A.J., Parthasarathy S. Lysophosphatidyl choline, a chemotactic factor for monocytes/T-lymphocytes is elevated in endometriosis. J Clin Endocrinol. 83:1998;2110-2113.
16. Tibes U., Hinder M., Scheuer W., Friebe W.G., Schramm S., Kaiser B. Phospholipase A2 is involved in chemotaxis of human leukocytes. Adv Exp Med Biol. 469:1999;189-197.
17. Nevalainen T.J., Haapamaki M.M., Gronroos J.M. Roles of secretory phospholipases A(2) in inflammatory diseases and trauma. Biochim Biophys Acta. 1488:2000;83-90.
18. Slack S.M., Turitto V.T. Fluid dynamic and hemorheologic considerations. Cardiovasc Pathol. 2:1993;11S-21S.
19. Kottke-Marchant K., Veenstra A.A., Marchant R.E. Human endothelial cell growth and coagulant function varies with respect to interfacial properties of polymeric substrates. J Biomed Mater Res. 30:1996;209-220.
20. Shankar R., de la Motte C.A., Poptic E.J., DiCorleto P.E. Thrombin receptor-activating peptides differentially stimulate platelet-derived growth factor production, monocytic cell adhesion, and E-selectin expression in human umbilical vein endothelial cells. J Biol Chem. 269:1994;13936-13941.
21. Takahashi M., Okazaki H., Ogata Y., Takeuchi K., Ikeda U., Shimada K. Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. Atherosclerosis. 161:2002;387-394.
22. Colles S.M., Chisolm G.M. Lysophosphatidylcholine-induced cellular injury in cultured fibroblasts involves oxidative events. J Lipid Res. 41:2000;1188-1980.
23. Marathe G.K., Silva A.R., de Castro Faria Neto H.C., Tjoelker L.W., Prescott S.M., Zimmerman G.A., et al. Lysophosphatidylcholine and lyso-PAF display PAF-like activity derived from contaminating phospholipids. J Lipid Res. 42:2001;1430-1437.
24. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 37:1959;911-917.
25. Huang Y.H., Schafer-Elinder L., Wu R., Claesson H.E., Frostegard J. Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. Clin Exp Immunol. 116:1999;326-331.
26. Baggiolini M., Dewald B., Moser B. Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Adv Immunol. 55:1994;97-179.
27. Pattison J.M., Nelson P.J., Huie P., Sibley R.K., Krensky A.M. RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J Heart Lung Transplant. 15:1996;1194-1199.
28. Aird W.C., Edelberg J.M., Weiler-Guettler H., Simmons W.W., Smith T.W., Rosenberg R.D. Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol. 138:1997;1117-1124.
29. Rosenberg R.D., Aird W.C. Vascular-bed-specific hemostasis and hypercoagulable states. New Engl J M. 340:1999;1555-1564.
30. Garlanda C., Dejana E. Heterogeneity of endothelial cells. Specific markers. Arterioscler Thromb Vasc Biol. 17:1997;1193-1202.
31. Colotta F., Sciacca F.L., Sironi M., Luini W., Rabiet M.J., Mantovani A. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol. 144:1994;975-985.
32. Rathanaswami P., Hachicha M., Sadick M., Schall T.J., McColl S.R. Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J Biol Chem. 268:1993;5834-5839.
33. Freeman J.E., Kuo W.Y., Drenger B., Barnett T.N., Levine M.A., Flavahan N.A. Analysis of lysophophatidylcholine-induced endothelial dysfunction. J Cardiovasc Pharmacol. 28:1996;345-352.
34. Cieslik K., Abrams C.S., Wu K.K. Up-regulation of endothelial nitric-oxide synthase promoter by the phosphatidylinositol 3-kinase gamma/Janus kinase 2/MEK-1-dependent pathway. J Biol Chem. 276:2001;1211-1219.
35. Kabarowski J.H., Zhu K., Le L.Q., Witte O.N., Xu Y. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science. 293:2001;702-705.
36. Zhu K., Baudhuin L.M., Hong G., Williams F.S., Cristina K.L., Kabarowski J.H., et al. Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. J Biol Chem. 276:2001;41325-41335.
37. Marin V., Farnarier C., Gres S., Kaplanski S., Su M.S., Dinarello C.A., et al. The p38 mitogen-activated protein kinase pathway plays a critical role in thrombin-induced endothelial chemokine production and leukocyte recruitment. Blood. 98:2001;667-673.
38. Murao K., Ohyama T., Imachi H., Ishida T., Cao W.M., Namihira H., et al. TNF-alpha stimulation of MCP-1 expression is mediated by the Akt/PKB signal transduction pathway in vascular endothelial cells. Biochem Biophys Res Commun. 276:2000;791-796.
39. Kawaguchi M., Onuchic L.F., Huang S.K. Activation of extracellular signal-regulated kinase (ERK)1/2, but not p38 and c-Jun N-terminal kinase, is involved in signaling of a novel cytokine, ML-1. J Biol Chem. 277:2002;15229-15232.
40. Parthasarathy S., Barnett J. Phospholipase A2 activity of low density lipoprotein: evidence for an intrinsic phospholipase A2 activity of apoprotein B-100. Proc Natl Acad Sci USA. 87:1990;9741-9745.
41. Macphee C.H. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol. 1:2001;121-125.
42. Yla-Herttuala S., Palinski W., Rosenfeld M.E., Parthasarathy S., Carew T.E., Butler S., et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 84:1989;1086-1095.
43. Toshima S., Hasegawa A., Kurabayashi M., Itabe H., Takano T., Sugano J., et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol. 20:2000;2243-2247.
44. Vadas P., Pruzanski W. Role of secretory phospholipases A2 in the pathobiology of disease. Lab Invest. 55:1986;391-404.
45. Rikitake Y., Hirata K., Yamashita T., Iwai K., Kobayashi S., Itoh H., et al. Expression of G2A, a receptor for lysophosphatidylcholine, by macrophages in murine, rabbit, and human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 22:2002;2049-2053.
46. Okita M., Gaudette D.C., Mills G.B., Holub B.J. Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine (lysoPC) in ovarian cancer patients. Int J Cancer. 71:1997;31-40.
47. Rodriguez F., Lopez I.M., Jover E. Plafibride treatment and serum lipids in hyperlipoproteinemias. J M. 18:1987;153-163.
48. Wong J.T., Tran K., Pierce G.N., Chan A.C., Karmin O., Choy P.C. Lysophosphatidylcholine stimulates the release of arachidonic acid in human endothelial cells. J Biol Chem. 273:1998;6830-6836.
49. Marfaing-Koka A., Devergne O., Gorgone G., Portier A., Schall T.J., Galanaud P., et al. Regulation of the production of the RANTES chemokine by endothelial cells. Synergistic induction by IFN-gamma plus TNF-alpha and inhibition by IL-4 and IL-13. J Immunol. 154:1995;1870-1878.
50. Goebeler M., Yoshimura T., Toksoy A., Ritter U., Brocker E.B., Gillitzer R. The chemokine repertoire of human dermal microvascular endothelial cells and its regulation by inflammatory cytokines. J Invest Dermatol. 108:1997;445-451.
51. Taub D.D., Conlon K., Lloyd A.R., Oppenheim J.J., Kelvin D.J. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta. Science. 260:1993;355-358.
52. Kovanen P.T., Pentikainen M.O. Secretory group II phospholipase A(2): a newly recognized acute-phase reactant with a role in atherogenesis. Circ Res. 86:2000;610-612.